NZ202210A - Pharmaceutical compositions containing haloallylates of levallorphan - Google Patents

Pharmaceutical compositions containing haloallylates of levallorphan

Info

Publication number
NZ202210A
NZ202210A NZ202210A NZ20221082A NZ202210A NZ 202210 A NZ202210 A NZ 202210A NZ 202210 A NZ202210 A NZ 202210A NZ 20221082 A NZ20221082 A NZ 20221082A NZ 202210 A NZ202210 A NZ 202210A
Authority
NZ
New Zealand
Prior art keywords
levallorphan
chloroallylate
sugar
pharmaceutical composition
examples
Prior art date
Application number
NZ202210A
Other languages
English (en)
Inventor
A Giudice
C Moulineau
L Manara
P Carminati
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NZ202210A publication Critical patent/NZ202210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ202210A 1981-10-19 1982-10-18 Pharmaceutical compositions containing haloallylates of levallorphan NZ202210A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8119607A FR2514644A1 (fr) 1981-10-19 1981-10-19 Composition pharmaceutique a action antagoniste peripherique des opiaces

Publications (1)

Publication Number Publication Date
NZ202210A true NZ202210A (en) 1985-03-20

Family

ID=9263165

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ202210A NZ202210A (en) 1981-10-19 1982-10-18 Pharmaceutical compositions containing haloallylates of levallorphan

Country Status (10)

Country Link
US (1) US4489079A (enExample)
EP (1) EP0077723B1 (enExample)
JP (1) JPS5874608A (enExample)
AT (1) ATE17942T1 (enExample)
AU (1) AU559451B2 (enExample)
DE (1) DE3269082D1 (enExample)
FR (1) FR2514644A1 (enExample)
IL (1) IL66853A (enExample)
NZ (1) NZ202210A (enExample)
ZA (1) ZA827063B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547820B1 (fr) * 1983-06-24 1986-04-18 Midy Spa Antagonistes peripheriques des opiaces
US5624958A (en) * 1987-12-31 1997-04-29 Isaacs; Charles E. Disinfecting contact lenses
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
DE19752080A1 (de) * 1997-11-25 1999-07-29 Karlsruhe Forschzent Verfahren zur Herstellung eines mehrkomponentigen, oxidischen Keramikpulvers
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP1244448B1 (en) * 1999-11-29 2009-05-27 Adolor Corporation Novel methods for the treatment and prevention of ileus
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
DK1694363T3 (en) * 2003-12-16 2014-03-24 Nektar Therapeutics Monodisperse PEGylated Naloxole Compositions
EP2190819B1 (en) 2007-08-09 2016-05-25 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
NZ600379A (en) 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US8436175B2 (en) * 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
RS56181B1 (sr) 2011-06-29 2017-11-30 Alkermes Inc Periferno delujuća opioidna jedinjenja
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Also Published As

Publication number Publication date
IL66853A0 (en) 1982-12-31
ZA827063B (en) 1983-07-27
AU559451B2 (en) 1987-03-12
US4489079A (en) 1984-12-18
EP0077723B1 (fr) 1986-02-12
FR2514644B1 (enExample) 1984-04-20
IL66853A (en) 1985-08-30
DE3269082D1 (en) 1986-03-27
AU8892282A (en) 1983-04-28
JPS5874608A (ja) 1983-05-06
FR2514644A1 (fr) 1983-04-22
ATE17942T1 (de) 1986-02-15
EP0077723A1 (fr) 1983-04-27

Similar Documents

Publication Publication Date Title
US4489079A (en) Pharmaceutical compositions having a peripheral antagonistic action with respect to opiates
EP1089733B1 (en) Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
SK61398A3 (en) Use of epinastine in the treatment of pain
HUT76852A (en) Use of benzotiophene derivatives for production of pharmaceutical compositions useful for inhibiting conditions associated with neuro-peptide y
AU779696B2 (en) Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
EP1087765B1 (en) Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome
Akubue The site of action of drugs on the isolated taenia caeci from the guinea-pig
Winter et al. Studies on synthetic curarizing agents
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
JPS6234036B2 (enExample)
Ilhan et al. TL-350, an ergoline derivative with dopamine receptor agonist properties.
JPS6019768A (ja) メチルレバロルフアニウム塩化合物およびその製造方法並びに薬剤
FR2538805A1 (fr) Procede de preparation d'halomethylate de levallorphan et composition pharmaceutique antagoniste peripherique des opiaces en contenant
MXPA00012364A (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
MXPA00012365A (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1435238A1 (en) Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
EP1464333A2 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
AU2003220743A1 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders